secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0000875320-25-000230
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex Q3 rev $3.08B (+11% YoY), FY guidance refined; povetacicept IgAN BLA on track
--------------------------------------------------------------------------------

- Q3 total revenue $3.08B (+11% vs Q3 2024); GAAP net income $1.1B, non-GAAP $1.2B.
- FY2025 revenue guidance raised to $11.9-12.0B; non-GAAP OpEx guidance $5.0-5.1B; tax rate lowered to 17-18%.
- Povetacicept Phase 3 IgAN enrollment complete; first BLA module submission to FDA by end of 2025.
- JOURNAVX: >300K prescriptions since March; CASGEVY: 165 cell collections, 39 infusions globally.
- Zimislecel T1D trial enrollment complete; dosing temporarily postponed pending manufacturing analysis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532025000230/0000875320-25-000230-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532025000230/vrtx-20251103.htm
  HTML page:      https://secwatch.observer/filing/0000875320-25-000230

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer